4.8 Article

Stroke Care 1 Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke

期刊

LANCET
卷 377, 期 9778, 页码 1681-1692

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(11)60516-3

关键词

-

资金

  1. Boehringer Ingelheim
  2. AstraZeneca
  3. Novartis
  4. Pfizer
  5. Sanofi-Aventis
  6. Otsuka Pharmaceutical

向作者/读者索取更多资源

Stroke is a major cause of death and disability worldwide. Without improvements in prevention, the burden will increase during the next 20 years because of the ageing population, especially in developing countries. Major advances have occurred in secondary prevention during the past three decades, which demonstrate the broader potential to prevent stroke. We review the main medical treatments that should be considered for most patients with transient ischaemic attack or ischaemic stroke in the acute phase and the long term, and draw attention to recent developments.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据